Home »
Academic Articles »
C »
ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine
ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine
Sehui Kim
(Progeneer, 12 Digital-ro 31-gil, Guro-gu, Seoul 08380, Republic of Korea)
Yeji Park
(Progeneer, 12 Digital-ro 31-gil, Guro-gu, Seoul 08380, Republic of Korea)
Jeonghun Kim
(Progeneer, 12 Digital-ro 31-gil, Guro-gu, Seoul 08380, Republic of Korea)
Sohyun Kim
(Progeneer, 12 Digital-ro 31-gil, Guro-gu, Seoul 08380, Republic of Korea)
Kyungmin Choi
(Progeneer, 12 Digital-ro 31-gil, Guro-gu, Seoul 08380, Republic of Korea)
Taegyun Kang
(Progeneer, 12 Digital-ro 31-gil, Guro-gu, Seoul 08380, Republic of Korea)
Inho Lee
(Progeneer, 12 Digital-ro 31-gil, Guro-gu, Seoul 08380, Republic of Korea)
Yong Taik Lim
(SKKU Advanced Institute of NanoTechnology (SAINT), Sungkyunkwan University (SKKU), Suwon 16419, Gyeonggi-do, Republic of Korea)
Soong Ho Um
(Progeneer, 12 Digital-ro 31-gil, Guro-gu, Seoul 08380, Republic of Korea)
Chul Kim
(Progeneer, 12 Digital-ro 31-gil, Guro-gu, Seoul 08380, Republic of Korea)
Journal: Vaccines
•
• MDPI AG
• ISSN: 2076-393X
Abstract
Despite numerous studies on cancer treatment, cancer remains a challenging disease to cure, even after decades of research. In recent years, the cancer vaccine has emerged as a promising approach for cancer treatment, offering few unexpected side effects compared to existing therapies. However, the cancer vaccine faces obstacles to commercialization due to its low efficacy. Particularly, the Toll-like receptor (TLR) adjuvant system, specifically the TLR 7/8 agonist, has shown potential for activating Th1 immunity, which stimulates both innate and adaptive immune responses through T cells. In this study, we developed ProLNG-S, a cholesterol-conjugated form of resiquimod (R848), to enhance immune efficacy by stimulating the immune system and reducing toxicity. ProLNG-S was formulated as ProLNG-001, a positively charged liposome, and co-administered with ovalbumin (OVA) protein in the B16-OVA model. ProLNG-001 effectively targeted secondary lymphoid organs, resulting in a robust systemic anti-tumor immune response and tumor-specific T cell activation. Consequently, ProLNG-001 demonstrated potential for preventing tumor progression and improving survival compared to AS01 by enhancing anti-tumor immunity.
Sehui Kim, Yeji Park, Jeonghun Kim, et al. (2023). "ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine". Vaccines. https://doi.org/10.3390/vaccines11091503